Occuity shortlisted for the LIFE SCIENCES & HEALTH TECH COMPANY OF THE YEAR at the Thames Valley Tech Awards 2024

We’re delighted to announce that Occuity has been selected as a finalist for the Hard Tech Investment of the Year award at the...

World Council of Optometry (WCO) has teamed up with CooperVision to launch an innovative tool designed to set a new standard in myopia manag

We are proud to announce that Occuity has been named the "Medtech & Healthtech StartUp of the Year" in the South East at the UK Startup...

As we approach the end of 2023, it's a fitting time to reflect on Occuity's progress throughout the year. Looking back, it's clear that...

We're very pleased to announce the successful completion of our Convertible Loan Note (CLN) investment round, which reached its target of...

Occuity is pleased to announce the filing of a new patent covering our novel approach to detecting and quantifying biomarkers in the eye....

We are pleased to announce a key milestone in Occuity's technology development strategy has been achieved. One of our recent patents,...

Over the past weekend, some of Occuity's senior leadership team headed to the vibrant city of San Francisco to participate in the eagerly...

Presentation of Internal Results on Investigating Effectiveness of SD1 Prototype to Identify Markers to Screen for Diabetes Occuity has...

The trailblazing technology and innovation behind the AX1 Axiometer™ have catapulted Occuity into the spotlight, earning us a coveted...

Occuity is pleased to announce our partnership with Argus Optik, a leading distributor of ophthalmic instruments and optical equipment...

Occuity is pleased to announce our partnership with Designs For Vision, a leading distributor of ophthalmic equipment for over 50 years....

Occuity is pleased to announce our partnership with Laméris, a leading distributor of ophthalmic equipment for over 100 years. Under this...

Myopia Action Month It's Myopia Action Month, (September 2023) a new global initiative launched this year with a clear objective to...

Accompanied by Mark Jenkins, Occuity's Chief Operating Officer, I packed my bags and, bleary-eyed, headed off out the door. Ahead of us,...

The submission of the PM1 Pachymeter for FDA 510 (k) approval represents a critical milestone in launching the PM1 in the US market. A...

We are delighted to announce that Mark Jenkins, the Chief Operating Officer of Occuity, and Richard Kadri-Langford, the Head of Digital...

As some of you may already know, we are committed to attracting exceptional talent to come and work with us and recently appointed...

Occuity is excited to announce the publication in the prestigious Journal of Ophthalmic & Physiological Optics (OPO) of the paper on the...